Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · Real-Time Price · USD
36.00
+0.35 (0.98%)
At close: Oct 20, 2025, 4:00 PM EDT
36.00
0.00 (0.00%)
After-hours: Oct 20, 2025, 4:00 PM EDT
Dianthus Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts that cover Dianthus Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $65.22, which forecasts a 81.17% increase in the stock price over the next year. The lowest target is $40 and the highest is $100.
Price Target: $65.22 (+81.17%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Dianthus Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
---|---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 5 | 6 |
Buy | 5 | 5 | 5 | 5 | 5 | 5 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 8 | 8 | 8 | 8 | 10 | 11 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Truist Securities | Truist Securities | Strong Buy Initiates $56 | Strong Buy | Initiates | $56 | +55.56% | Oct 14, 2025 |
Clear Street | Clear Street | Strong Buy Initiates $100 | Strong Buy | Initiates | $100 | +177.78% | Sep 17, 2025 |
Stifel | Stifel | Strong Buy Maintains $52 → $65 | Strong Buy | Maintains | $52 → $65 | +80.56% | Sep 12, 2025 |
Wedbush | Wedbush | Buy Maintains $42 → $44 | Buy | Maintains | $42 → $44 | +22.22% | Sep 12, 2025 |
Raymond James | Raymond James | Buy Reiterates $56 → $63 | Buy | Reiterates | $56 → $63 | +75.00% | Sep 9, 2025 |
Financial Forecast
Revenue This Year
2.41M
from 6.24M
Decreased by -61.41%
Revenue Next Year
2.15M
from 2.41M
Decreased by -10.52%
EPS This Year
-3.46
from -2.55
EPS Next Year
-3.62
from -3.46
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 5.3M | 6.3M | |||
Avg | 2.4M | 2.2M | |||
Low | 1.3M | n/a |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -15.3% | 161.8% | |||
Avg | -61.4% | -10.5% | |||
Low | -78.7% | - |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -3.21 | -2.96 | |||
Avg | -3.46 | -3.62 | |||
Low | -3.75 | -4.82 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | |||
Avg | - | - | |||
Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.